Core Viewpoint - The market anticipates Zoetis (ZTS) will report a year-over-year increase in earnings driven by higher revenues in its upcoming earnings report for the quarter ended March 2025, with a consensus EPS estimate of $1.40, reflecting a 1.5% increase from the previous year [1][3]. Earnings Expectations - The expected revenue for Zoetis is $2.19 billion, indicating no change from the year-ago quarter [3]. - The stock may experience upward movement if the actual earnings exceed expectations, while a miss could lead to a decline [2]. Estimate Revisions - The consensus EPS estimate has been revised down by 0.23% over the last 30 days, indicating a bearish sentiment among analysts regarding the company's earnings prospects [4]. - The Most Accurate Estimate for Zoetis is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -1.15% [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from the consensus estimate, with a strong predictive power for positive readings [7][8]. - Zoetis currently holds a Zacks Rank of 3, making it challenging to predict a beat on the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, Zoetis had an earnings surprise of +2.19%, reporting $1.40 per share against an expectation of $1.37 [12]. - Over the past four quarters, Zoetis has consistently beaten consensus EPS estimates [13]. Industry Comparison - Neurocrine Biosciences (NBIX), another player in the Zacks Medical - Drugs industry, is expected to report earnings of $0.42 per share, with revenues projected at $569.46 million, reflecting a 10.5% increase from the previous year [17]. - Neurocrine's consensus EPS estimate has been revised down by 5.2% over the last 30 days, resulting in an Earnings ESP of -37.31% [18].

Core Insights - Xylem reported $2.07 billion in revenue for Q1 2025, a year-over-year increase of 1.8% and an EPS of $1.03 compared to $0.90 a year ago, exceeding Zacks Consensus Estimates for both revenue and EPS [1] - The company delivered a revenue surprise of +1.26% and an EPS surprise of +8.42% compared to analyst expectations [1] Revenue Breakdown - Measurement & Control Solutions generated $490 million, exceeding the average estimate of $466.09 million, reflecting a year-over-year increase of +6.1% [4] - Applied Water revenue was $435 million, slightly below the average estimate of $428.62 million, showing a year-over-year decrease of -0.2% [4] - Water Infrastructure revenue reached $581 million, surpassing the average estimate of $575.20 million, with a year-over-year increase of +1.2% [4] - Water Solutions and Services reported $563 million, slightly below the estimated $564.67 million [4] Stock Performance - Xylem's shares have returned -3% over the past month, compared to a -0.8% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Viewpoint - DexCom, Inc. is set to release its first-quarter 2025 results on May 1, with expectations of revenue growth and potential challenges ahead [1][3][4]. Financial Performance - The Zacks Consensus Estimate for revenues is $1.02 billion, reflecting a 10.3% increase from the previous year [3]. - The consensus estimate for earnings is 33 cents per share, indicating a 3.1% year-over-year growth [3]. - In the last reported quarter, DexCom's earnings missed estimates by 10% but outperformed in three of the last four quarters, with an average surprise of 5.86% [1]. Market Dynamics - DexCom's performance is bolstered by an expanded U.S. prescriber base and improved coverage by major pharmacy benefit managers (PBMs) [5]. - The company has seen a record number of new patient starts and added 50,000 new clinicians in 2024, indicating strong commercial execution [6]. - U.S. revenues improved by 4% year-over-year in the fourth quarter, following a decline in the third quarter [7]. International Expansion - The international segment grew by 17% year-over-year in the last quarter, driven by the launch of G7 in Australia and coverage for Dexcom ONE+ in France and New Zealand [7][8]. - The return to growth in Japan, aided by a new sales structure, is a significant highlight [8]. Product Development - Stelo, an over-the-counter continuous glucose monitor, has gained traction with over 140,000 users in its first four months [8]. - DexCom plans to enhance Stelo's adoption through product iterations and partnerships, including integration with Oura Ring for comprehensive health monitoring [9]. Financial Outlook - DexCom projects full-year 2025 revenue of $4.6 billion, representing organic growth of 14% [10]. - The company anticipates continued margin improvement as it converts its installed base to G7 and scales manufacturing [10]. - DexCom holds a strong cash position of $2.58 billion, providing financial flexibility for strategic initiatives [11].

Altria (MO) came out with quarterly earnings of $1.23 per share, beating the Zacks Consensus Estimate of $1.17 per share. This compares to earnings of $1.15 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 5.13%. A quarter ago, it was expected that this owner of Philip Morris USA, the nation's largest cigarette maker would post earnings of $1.27 per share when it actually produced earnings of $1.29, delivering a surprise of 1.5 ...

Entergy (ETR) came out with quarterly earnings of $0.82 per share, beating the Zacks Consensus Estimate of $0.62 per share. This compares to earnings of $0.54 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 32.26%. A quarter ago, it was expected that this power company would post earnings of $0.63 per share when it actually produced earnings of $0.66, delivering a surprise of 4.76%.Over the last four quarters, the company has ...

Core Insights - The U.S. construction sector is experiencing a deceleration, influenced by high borrowing costs, labor shortages, material price volatility, and regulatory complexity [1] Group 1: Sector Performance - Public sector investments in infrastructure and manufacturing have supported growth, while residential remodeling and selective new home construction have posed challenges [1] - The construction sector's total earnings have decreased by 20% year-over-year, with revenues down by 4.2% [2] - Approximately 35.3% of the construction sector's market capitalization on the S&P 500 Index has reported earnings, with 57.1% beating EPS estimates and 42.9% surpassing revenue estimates [2] Group 2: Influencing Factors - Federal spending through the Infrastructure Investment and Jobs Act (IIJA) has been a significant tailwind, particularly in transportation, water infrastructure, and broadband projects [3] - Industrial construction projects related to the CHIPS Act and Inflation Reduction Act have also contributed to growth, focusing on semiconductor fabs, EV battery plants, and clean energy facilities [3] Group 3: Residential Market Challenges - The residential construction market faces high mortgage rates, seasonal impacts, inflationary pressures, and rising costs, which have negatively affected performance [4] - Homebuilders are under pressure due to increased incentives and lower average selling prices, impacting margins [4] Group 4: Commercial Construction Insights - The commercial construction market shows mixed but resilient performance, with industrial and warehouse projects benefiting from e-commerce and supply chain reshoring [5] - Data center construction is gaining traction due to cloud computing and AI infrastructure needs, while hospitality construction is recovering alongside rebounding travel [5] Group 5: Q1 Earnings Expectations - The construction sector is expected to see a 12.8% decline in earnings for Q1, a decrease from the previous quarter's growth of 1.1% [6] - Revenues are projected to decline by 3.3%, indicating a slowdown from the prior quarter's growth of 1.6% [6] Group 6: Company Highlights - Dream Finders Homes is expected to report a first-quarter EPS of 61 cents, reflecting a 10.9% growth year-over-year [11] - Primoris Services anticipates a first-quarter EPS of 72 cents, representing a 53.2% increase from the previous year [13] - Potlatch is projected to report a first-quarter EPS of 20 cents, improving from break-even earnings a year ago [14] - Martin Marietta Materials expects a first-quarter EPS of $1.92, a slight decline from the previous year [15] - MasTec is likely to report a first-quarter EPS of 34 cents, indicating a significant 361.5% growth year-over-year [16]

General Motors Co GM is set to report its first-quarter earnings on Tuesday before the market opens. Wall Street expects earnings per share of $2.73 on revenues of $43.15 billion.The stock has gained 2.65% over the past year but remains down 8% year-to-date, as tariff headlines and macro noise kept the auto sector spinning its wheels.Let's take a look at what the charts are signaling for GM stock ahead of earnings.Read Also: Automakers Are Struggling With Tariffs And EV Competition, Say AnalystsGM Technical ...

Core Viewpoint - Becton Dickinson and Company (BDX) is set to report its second-quarter fiscal 2025 results, with expectations of revenue growth driven by advancements in its medical segments and product adoption, despite some challenges in the market [1][11]. Group 1: BD Medical Segment - The BD Medical segment is expected to see significant revenue growth, with estimates of $2.85 billion, reflecting a 16.3% year-over-year increase, aided by the adoption of the BD PIVO Pro Needle-free Blood Collection Device [4][2]. - Management has made progress in the Connected Care strategy and received FDA clearance for new monitoring devices, which is likely to enhance revenue in this segment [3]. Group 2: BD Life Sciences Segment - The BD Life Sciences segment's revenues are estimated at $1.29 billion, a slight decline of 1.3% year-over-year, influenced by the expansion of fingertip blood testing and the success of the BD Onclarity HPV Assay [7][6]. - The segment is advancing in the high-volume molecular testing market, which is expected to contribute positively to revenues [6]. Group 3: BD Interventional Segment - The BD Interventional segment is projected to generate $1.33 billion in revenue, up 2.8% year-over-year, supported by ongoing product adoption and new applications in advanced tissue regeneration [10][9]. - The segment has received EU approval for new products, which is expected to drive further growth [8]. Group 4: Overall Financial Estimates - The overall revenue consensus estimate for the second quarter is $5.37 billion, indicating a 6.4% increase from the previous year, with EPS expected to rise by 3.5% to $3.28 [11]. Group 5: Valuation and Market Performance - BD's forward 12-month price-to-earnings (P/E) ratio is 13.6X, which is below the industry average of 16.6X, suggesting a potential undervaluation relative to peers [20][21]. - Over the past three months, BD's shares have declined by 16.3%, underperforming both the medical supplies sector and the broader market [14][18]. Group 6: Long-Term Prospects - The company is investing in its U.S. manufacturing network to enhance capacity for critical medical devices, which is expected to benefit the Medication Delivery Solutions business in the long term [22]. - BD's collaboration with Biosero aims to enhance drug discovery processes, indicating a commitment to innovation and growth in the Life Sciences segment [23].

Core Viewpoint - Amcor Plc (AMCR) is set to report its third-quarter fiscal 2025 results on April 30, with revenue expectations of $3.51 billion, reflecting a 2.9% increase year-over-year, and earnings per share estimated at 18 cents, indicating no change from the previous year [1] Financial Estimates - The Zacks Consensus Estimate for AMCR's fiscal third-quarter revenues is $3.51 billion, indicating a 2.9% growth from the year-ago figure [1] - The consensus estimate for earnings is 18 cents per share, which has decreased by 5.3% over the past 60 days [1][2] - The Earnings ESP for AMCR is -2.17%, suggesting a lower likelihood of an earnings beat this quarter [3] Volume and Segment Performance - Amcor's total volume growth was negative for seven consecutive quarters until Q4 of fiscal 2024, where it saw a 1% increase, followed by 2% growth in both Q1 and Q2 of fiscal 2025 [4] - The Flexible segment is projected to achieve a volume growth of 4.9% in Q3, with sales expected to reach $2.68 billion, representing a 3% year-over-year increase [7] - The Rigid Packaging segment is estimated to have a 4.1% rise in volumes, with sales projected at $0.85 billion, indicating a 4% year-over-year growth [8] Market Dynamics - Amcor has been facing supply shortages and price volatility in certain resins and raw materials due to market dynamics and inflation, which are expected to impact Q3 earnings [6] - Overall price/mix benefits are anticipated to be a negative 1.9% for the quarter [5] Recent Developments - The European Commission has approved the merger between Amcor and Berry Global Group, which is set to close on April 30, 2025, pending certain conditions [9] - Over the past year, Amcor's shares have increased by 10.6%, outperforming the industry, which saw a 2.3% decline [10]

Core Viewpoint - The market anticipates a year-over-year decline in Cummins' earnings due to lower revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - Cummins is expected to report quarterly earnings of $4.82 per share, reflecting a year-over-year decrease of 5.5% [3]. - Revenue projections stand at $8.07 billion, which is a 4% decline from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 7.13% over the last 30 days, indicating a bearish sentiment among analysts regarding the company's earnings prospects [4][10]. - The Most Accurate Estimate is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -1.79% [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from consensus estimates, with positive readings being more predictive of earnings beats [5][7]. - Stocks with a positive Earnings ESP and a Zacks Rank of 1, 2, or 3 have historically shown a nearly 70% chance of delivering a positive surprise [8]. Historical Performance - In the last reported quarter, Cummins exceeded the expected earnings of $4.68 per share by delivering $5.16, resulting in a surprise of +10.26% [12]. - Over the past four quarters, Cummins has beaten consensus EPS estimates three times [13]. Conclusion - Despite the potential for an earnings beat, various factors can influence stock movement, making it essential to consider other elements beyond just earnings results [14][16].